TY - T1的冻结的步态PD JF -神经学乔-神经病学SP - 1712 LP -首页 1721 - 10.1212 / WNL.56.12.1712六世- 56 - 12 AU - n . Giladi AU - m·p·麦克德莫特盟- s Fahn AU - s Przedborski AU - j .扬科维奇AU - m·斯特恩AU - c·坦纳盟帕金森研究小组Y1 - 2001/06/26 UR - //www.ez-admanager.com/content/56/12/1712.abstract N2 -目的:研究冻结的步态PD的发展。背景:冻结的步态是一种常见的,禁用,并在PD症状知之甚少。方法:作者分析了数据从800年早期PD患者的Deprenyl和生育酚抗氧化治疗震颤麻痹(DATATOP)临床试验被分配或安慰剂,Deprenyl,生育酚,或者Deprenyl和生育酚。主要结果测量指标是时间从随机化到冻结的步态评分统一帕金森病评定量表(UPDRS)成为积极的。结果:57例(7.1%)有冻结的步态研究入口和193(26%)的患者的症状随访期结束。冻结的步态在基线明显比没有更先进的疾病症状,以总UPDRS和Hoehn Yahr阶段。高基线风险因素发展中冻结在随访期间步态PD的发病与步态障碍;更高的分数的刚性,姿势不稳,动作迟缓和演讲;和疾病持续时间更长。相比之下,地震强烈风险减少步态的冻结。 At the end of follow-up, the signs most strongly associated with the freezing phenomenon were gait, balance, and speech disorders, not rigidity or bradykinesia. Deprenyl treatment was strongly associated with a decreased risk for developing freezing of gait; tocopherol had no effect. Conclusions: Freezing of gait is directly related to duration of PD. Risk factors at onset of disease are the absence of tremor and PD beginning as a gait disorder. The development of freezing of gait in the course of the illness is strongly associated with the development of balance and speech problems, less so with the worsening of bradykinesia, and is not associated with the progression of rigidity. These results support the concept that the freezing phenomenon is distinct from bradykinesia. Deprenyl, in the absence of l-dopa, was found to be an effective prophylactic treatment and should be considered for patients with PD who have an onset of gait difficulty. ER -